EUVIMEDEUVIMED entdecken
Crossref

Levetiracetam attenuates experimental ulcerative colitis through promoting Nrf2/HO-1 antioxidant and inhibiting NF-κB, proinflammatory cytokines and iNOS/NO pathways

Keyvan Amirshahrokhi, Mahsa Imani

International Immunopharmacology · 2023-06 · 119 · 110165

DOI: 10.1016/j.intimp.2023.110165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-06. Verfasst von Keyvan Amirshahrokhi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran. Electronic address: amirshahrokhi@gmail.com. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a serious inflammatory disease of the colon. The pathogenic mechanisms of UC involve the activation of inflammatory and oxidative stress responses in the colon. Levetiracetam is an antiepileptic drug with anti-inflammatory and antioxidant effects. The aim of this study was to investigate the potential protective effect of levetiracetam against UC in a mouse model. UC was induced in mice by intrarectal administration of acetic acid and then mice were treated with levetiracetam (50 or 100 mg/kg/day, i.p.) for three days. The colonic tissue samples were dissected for biochemical, RT-PCR and immunofluorescence analysis. Results showed that levetiracetam treatment significantly decreased colonic mucosal injury as evidenced by the macroscopic and histopathological analysis. Levetiracetam induced Nrf2/HO-1 and antioxidants while reduced lipid peroxidation and myeloperoxidase activity in colon tissue. Levetiracetam treatment decreased NF-κB activity and the expression of proinflammatory mediators TNF-α, IL-6, IL-1β, IFN-γ, MCP-1 and ICAM-1. The colonic levels of anti-inflammatory cytokines IL-10 and TGF-β1 were increased by levetiracetam treatment. Furthermore, levetiracetam significantly diminished iNOS expression and NO production in colon tissue. These findings suggest that levetiracetam ameliorates the severity of UC in mice through the regulation of inflammatory and oxidative responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMiceAnimalsNF-kappa BAntioxidantsCytokinesLevetiracetamNF-E2-Related Factor 2Signal TransductionColonAnti-Inflammatory AgentsDextran Sulfate

Stichwörter der Autor:innen

CytokinesLevetiracetamNF-κBNrf2/HO-1Ulcerative ColitisiNOS//NO

Substanzen

NF-kappa BAntioxidantsCytokinesLevetiracetamNF-E2-Related Factor 2Anti-Inflammatory AgentsDextran Sulfate

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran. Electronic address: amirshahrokhi@gmail.com.
  • School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran. Electronic address: imanimahsa72@gmail.com.

Zitieren

APA

Amirshahrokhi, K., & Imani, M. (2023). Levetiracetam attenuates experimental ulcerative colitis through promoting Nrf2/HO-1 antioxidant and inhibiting NF-κB, proinflammatory cytokines and iNOS/NO pathways. International Immunopharmacology, 119, 110165. https://doi.org/10.1016/j.intimp.2023.110165

Vancouver

Amirshahrokhi K, Imani M. Levetiracetam attenuates experimental ulcerative colitis through promoting Nrf2/HO-1 antioxidant and inhibiting NF-κB, proinflammatory cytokines and iNOS/NO pathways. International Immunopharmacology. 2023;119:110165. doi:10.1016/j.intimp.2023.110165

BibTeX
@article{Amirshahrokhi2023,
  author = {Amirshahrokhi, Keyvan and Imani, Mahsa},
  title = {Levetiracetam attenuates experimental ulcerative colitis through promoting Nrf2/HO-1 antioxidant and inhibiting NF-κB, proinflammatory cytokines and iNOS/NO pathways},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {119},
  pages = {110165},
  doi = {10.1016/j.intimp.2023.110165}
}
Kostenlos starten →